Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance

Arora, Prerna; Kempf, Amy; Nehlmeier, Inga; Graichen, Luise; Sidarovich, Anzhalika; Winkler, Martin Sebastian; Schulz, Sebastian; Jäck, Hans‐Martin; Stankov, Metodi V.; Behrens, Georg M. N.; Pöhlmann, Stefan; Hoffmann, Markus

doi:10.1038/s41423-021-00772-y

Cited by 43 publications

(39 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, at the 8-month follow-up, 19% and 6% did not show neutralization against wild-type or cross-neutralization against the B.1.617.2 (delta) variant, respectively. Our results of live virus neutralization at peak levels after second vaccination are in concordance with current literature, showing only a slightly impaired vaccine-induced humoral response to the B.1.617.2 (delta) variant after two-dose vaccination [ 9 , 18 , 19 ]. Poorer cross-neutralization is seen in variants of concern with mutations resulting in amino acid substitutions K417N, E484K and N501Y in the receptor-binding site as demonstrated for example for the immune-escaping B.1.351 (beta) variant [ 20 , 21 ].…”

Section: Discussionsupporting

confidence: 92%

Neutralizing antibody activity against the B.1.617.2 (delta) variant 8 months after two-dose vaccination with BNT162b2 in health care workers

Benning

Morath

Bartenschlager

et al. 2022

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Objectives Humoral immunity wanes over time after two-dose BNT162b2 vaccination. Emerging variants of concern, such as the B.1.617.2 (delta) variant, are increasingly responsible for breakthrough infections due to their higher transmissibility and partial immune escape. Longitudinal data on neutralization against the B.1.617.2 (delta) variant are urgently needed to guide vaccination strategies. Methods In this prospective longitudinal observational study, anti-S1 IgG and neutralizing surrogate antibodies were measured in 234 collected samples from 60 health care workers after two-dose vaccination with BNT162b2 at five different time points over an 8-month period. In addition, antibodies against various SARS-CoV-2 epitopes, neutralization against wild-type, and cross-neutralization against the B.1.617.2 (delta) variant using a live virus assay were measured 6 weeks (second time point) and 8 months (last time point) after first vaccine dose. Results Median (IQR) anti-S1 IgG, surrogate neutralizing, and receptor-binding domain antibodies decreased significantly from a maximum level of 147 (102–298), 97 (96–98), and 20,159 (19,023–21,628) to 8 (4–13), 92 (80–96), and 15,324 (13,055–17,288) at the 8-month follow-up, respectively ( P <0.001 for all). Neutralization against the B.1.617.2 (delta) variant was detectable in 36/36 (100%) participants 6 weeks and in 50/53 (94%) participants 8 months after first vaccine dose. Median (IQR) ID 50 as determined by a live virus assay decreased from 160 (80–320) to 40 (20–40) ( P <0.001). Conclusions Although humoral immunity wanes over time after two-dose BNT162b2 vaccination in healthy individuals, most individuals still had detectable neutralizing activity against the B.1.617.2 (delta) variant after 8 months.

show abstract

Section: Discussionsupporting

confidence: 92%

Neutralizing antibody activity against the B.1.617.2 (delta) variant 8 months after two-dose vaccination with BNT162b2 in health care workers

Benning

Morath

Bartenschlager

et al. 2022

Clinical Microbiology and Infection

View full text Add to dashboard Cite

show abstract

“…Furthermore, as recently reported, no impairment of neutralization sensitivity of the Delta variant and its sublineages have been already observed, except for the Delta Plus that showed resistance for monoclonal antibody used for COVID-19 patient treatment. 15 In conclusion, considering the recent concern regarding the rapid rise of this novel variant mainly across Europe and the constellation of mutation into the S protein, our findings reinforce how crucial is the implementation of nonpharmaceutical measures together with the need for active monitoring, in containing and preventing the spread of any potential emerging viral strains with possible implications for public health policies and immunization strategies.…”

Section: Discussionsupporting

confidence: 70%

SARS‐CoV‐2 AY.4.2 variant circulating in Italy: Genomic preliminary insight

Angeletti

Giovanetti

Fogolari

et al. 2021

Journal of Medical Virology

View full text Add to dashboard Cite

The appearance of emerging variants of SARS-CoV-2 carrying mutations into the spike protein has recently raised concern with respect to tracking their transmission and mitigating the impact in the evolving pandemic across countries. AY.4.2, a recently detected Delta variant sublineage, is considered a new variant under investigation (VUI) as it carries specific genetic signatures present in the spike protein, called Y145H and A222V. Here, using genomic epidemiology, we provide the first preliminary insight regarding the circulation of this emerging VUI in Italy.

show abstract

“…The phylogeny of Delta is more structured than that of other variants of concern, and its characteristic mutations have accumulated gradually [14]. While Delta clearly has increased fitness compared to ancestral strains, whether its sublineages change its properties further is less clear [15][16][17]. Still, adaptive evolution of SARS-CoV-2 in the human genome continues [18], highlighting the need for surveillance of novel variants.…”

Section: Introductionmentioning

confidence: 99%

The rise and spread of the SARS-CoV-2 AY.122 lineage in Russia

Klink

Safina

Nabieva

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundDelta has outcompeted most preexisting variants of SARS-CoV-2, becoming the globally predominant lineage by mid-2021. Its subsequent evolution has led to emergence of multiple sublineages, many of which are well-mixed between countries.AimHere, we aim to study the emergence and spread of the Delta lineage in Russia.MethodsWe use a phylogeographic approach to infer imports of Delta sublineages into Russia, and phylodynamic models to assess the rate of their spread.ResultsWe show that nearly the entire Delta epidemic in Russia has probably descended from a single import event despite genetic evidence of multiple Delta imports. Indeed, over 90% of Delta samples in Russia are characterized by the nsp2:K81N+ORF7a:P45L pair of mutations which is rare outside Russia, putting them in the AY.122 sublineage. The AY.122 lineage was frequent in Russia among Delta samples from the start, and has not increased in frequency in other countries where it has been observed, suggesting that its high prevalence in Russia has probably resulted from a random founder effect.ConclusionThe apartness of the genetic composition of the Delta epidemic in Russia makes Russia somewhat unusual, although not exceptional, among other countries.

show abstract

Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance

Cited by 43 publications

References 11 publications

Neutralizing antibody activity against the B.1.617.2 (delta) variant 8 months after two-dose vaccination with BNT162b2 in health care workers

Neutralizing antibody activity against the B.1.617.2 (delta) variant 8 months after two-dose vaccination with BNT162b2 in health care workers

SARS‐CoV‐2 AY.4.2 variant circulating in Italy: Genomic preliminary insight

The rise and spread of the SARS-CoV-2 AY.122 lineage in Russia

Contact Info

Product

Resources

About